LPL and coronary artery disorder: We selected triglyceride lowering genetic variants located in the genes encoding ANGPTL3, ANGPTL4, APOC3 and LPL and conducted drug target MR on primary outcomes including coronary artery disease (CAD) and type 2 diabetes (T2D), and secondary outcomes including apolipoprotein-B (apoB), waist-to-hip ratio (WHR), body mass index, and 233 metabolic biomarkers.